JP2014516536A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014516536A5 JP2014516536A5 JP2014511948A JP2014511948A JP2014516536A5 JP 2014516536 A5 JP2014516536 A5 JP 2014516536A5 JP 2014511948 A JP2014511948 A JP 2014511948A JP 2014511948 A JP2014511948 A JP 2014511948A JP 2014516536 A5 JP2014516536 A5 JP 2014516536A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- vector
- vector according
- immunogenic composition
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013598 vector Substances 0.000 claims 19
- 230000002163 immunogen Effects 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 239000002773 nucleotide Substances 0.000 claims 6
- 125000003729 nucleotide group Chemical group 0.000 claims 6
- 108091026890 Coding region Proteins 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 239000013603 viral vector Substances 0.000 claims 5
- 210000004436 artificial bacterial chromosome Anatomy 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 210000000234 capsid Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 238000004806 packaging method and process Methods 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 3
- 102000040430 polynucleotide Human genes 0.000 claims 3
- 239000002157 polynucleotide Substances 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 241000701161 unidentified adenovirus Species 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108700026244 Open Reading Frames Proteins 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 230000000295 complement effect Effects 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108090000565 Capsid Proteins Proteins 0.000 claims 1
- 102100023321 Ceruloplasmin Human genes 0.000 claims 1
- 241001217856 Chimpanzee adenovirus Species 0.000 claims 1
- 101710145505 Fiber protein Proteins 0.000 claims 1
- 101710094396 Hexon protein Proteins 0.000 claims 1
- 101710173835 Penton protein Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 210000004102 animal cell Anatomy 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1108879.6 | 2011-05-25 | ||
| GBGB1108879.6A GB201108879D0 (en) | 2011-05-25 | 2011-05-25 | Vector |
| PCT/GB2012/000467 WO2012172277A1 (en) | 2011-05-25 | 2012-05-25 | Simian adenovirus and hybrid adenoviral vectors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014516536A JP2014516536A (ja) | 2014-07-17 |
| JP2014516536A5 true JP2014516536A5 (OSRAM) | 2015-07-09 |
| JP6230527B2 JP6230527B2 (ja) | 2017-11-15 |
Family
ID=44279666
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014511948A Active JP6230527B2 (ja) | 2011-05-25 | 2012-05-25 | サルアデノウイルス及び雑種アデノウイルスベクター |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US9714435B2 (OSRAM) |
| EP (2) | EP3321367B1 (OSRAM) |
| JP (1) | JP6230527B2 (OSRAM) |
| CN (1) | CN103930551B (OSRAM) |
| AU (1) | AU2012270144B2 (OSRAM) |
| BR (1) | BR112013030222A2 (OSRAM) |
| CA (1) | CA2837274C (OSRAM) |
| DK (1) | DK2714916T3 (OSRAM) |
| ES (1) | ES2659183T3 (OSRAM) |
| FR (1) | FR21C1026I1 (OSRAM) |
| GB (1) | GB201108879D0 (OSRAM) |
| NO (2) | NO2714916T3 (OSRAM) |
| RU (1) | RU2013152648A (OSRAM) |
| SG (2) | SG195181A1 (OSRAM) |
| WO (1) | WO2012172277A1 (OSRAM) |
| ZA (1) | ZA201309016B (OSRAM) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
| MX358019B (es) * | 2012-05-18 | 2018-08-02 | Univ Pennsylvania | Adenovirus de simio de la subfamilia e a1302, a1320, a1331 y a1337 y sus usos. |
| JP6576326B2 (ja) | 2013-03-14 | 2019-09-18 | ソーク インスティテュート フォー バイオロジカル スタディーズ | 腫瘍溶解性アデノウイルス組成物 |
| GB201413530D0 (en) | 2014-07-30 | 2014-09-10 | Isis Innovation | Treatment and prevention of malaria |
| KR102535670B1 (ko) * | 2015-06-12 | 2023-05-22 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 아데노바이러스 폴리뉴클레오티드 및 폴리펩티드 |
| AU2017222568B2 (en) | 2016-02-23 | 2020-09-10 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| KR20220163505A (ko) | 2016-02-23 | 2022-12-09 | 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현 |
| GB2549809C (en) | 2016-06-23 | 2022-11-30 | Univ Oxford Innovation Ltd | Vector |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| CN106916851A (zh) * | 2017-03-01 | 2017-07-04 | 广州恩宝生物医药科技有限公司 | 一种复制缺陷型人14型腺病毒载体及其制备方法和应用 |
| KR20230166145A (ko) | 2017-03-15 | 2023-12-06 | 옥스포드 바이오메디카(유케이) 리미티드 | 방법 |
| SG11201910101SA (en) | 2017-05-08 | 2019-11-28 | Gritstone Oncology Inc | Alphavirus neoantigen vectors |
| GB201708444D0 (en) | 2017-05-26 | 2017-07-12 | Univ Oxford Innovation Ltd | Compositions and methods for inducing an immune response |
| KR20200118029A (ko) | 2018-01-04 | 2020-10-14 | 아이코닉 테라퓨틱스, 인코포레이티드 | 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법 |
| CN112292449A (zh) | 2018-04-09 | 2021-01-29 | 萨克生物研究学院 | 具有增强的复制特性的溶瘤腺病毒组合物 |
| GB201812647D0 (en) * | 2018-08-03 | 2018-09-19 | Chancellor Masters And Scholars Of The Univ Of Oxford | Viral vectors and methods for the prevention or treatment of cancer |
| GB201814141D0 (en) * | 2018-08-30 | 2018-10-17 | Univ Oxford Innovation Ltd | Method and compositions for producing a virus |
| CN109797168A (zh) * | 2018-09-28 | 2019-05-24 | 广州佰芮慷生物科技有限公司 | 一种重组腺病毒的表达载体SAd23-L |
| WO2020074908A2 (en) | 2018-10-10 | 2020-04-16 | Oxford University Innovation Limited | Treatment and prevention of malaria |
| GB201818084D0 (en) | 2018-11-06 | 2018-12-19 | Univ Oxford Innovation Ltd | Compositions and methods |
| CN109602901B (zh) * | 2019-01-08 | 2022-05-27 | 成都迈科康生物科技有限公司 | 一种带状疱疹病毒疫苗及其制备方法和应用 |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| TW202408568A (zh) * | 2019-05-22 | 2024-03-01 | 美商基利科學股份有限公司 | Tlr7調節化合物及hiv疫苗之組合 |
| CA3141454A1 (en) | 2019-05-22 | 2020-11-26 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| CN114072516B (zh) | 2019-05-30 | 2025-01-14 | 磨石生物公司 | 经修饰的腺病毒 |
| US11497808B2 (en) | 2019-09-30 | 2022-11-15 | Gilead Sciences, Inc. | HBV vaccines and methods treating HBV |
| AU2020384323A1 (en) | 2019-11-14 | 2022-06-02 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | Vaccines based on mutant calr and jak2 and their uses |
| JP2023512519A (ja) | 2020-01-31 | 2023-03-27 | ベス イスラエル ディーコネス メディカル センター インコーポレイテッド | コロナウイルス感染症を予防および処置するための組成物および方法-sars-cov-2ワクチン |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| GB202003611D0 (en) | 2020-03-12 | 2020-04-29 | Univ Oxford Innovation Ltd | Stabilised viral fusion proteins |
| WO2021181100A1 (en) | 2020-03-13 | 2021-09-16 | Oxford University Innovation Limited | Compositions and methods for inducing an immune response |
| RU2720614C9 (ru) * | 2020-04-23 | 2021-02-09 | федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации | Иммунобиологическое средство и способ его использования для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома SARS-CoV-2 (варианты) |
| AU2021269783A1 (en) | 2020-05-11 | 2022-12-08 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| TWI867224B (zh) * | 2020-06-08 | 2024-12-21 | 中央研究院 | 重組抗體或片段,以及其用途 |
| WO2022002894A1 (en) | 2020-06-29 | 2022-01-06 | Janssen Vaccines & Prevention B.V. | Vaccine combination against respiratory syncytial virus infection |
| US20230302119A1 (en) | 2020-07-06 | 2023-09-28 | Janssen Pharmaceuticals, Inc. | Stabilized Corona Virus Spike Protein Fusion Proteins |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| GB2596820A (en) | 2020-07-07 | 2022-01-12 | Spicona Inc | Combination vaccine |
| JP2023541108A (ja) | 2020-08-06 | 2023-09-28 | グリットストーン バイオ インコーポレイテッド | マルチエピトープワクチンカセット |
| EA037291B9 (ru) * | 2020-08-22 | 2021-11-24 | федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации | Экспрессионный вектор для создания иммунобиологического средства для индукции специфического иммунитета против вируса тяжелого острого респираторного синдрома sars-cov-2 (варианты) |
| WO2022058700A1 (en) | 2020-09-15 | 2022-03-24 | Imperial College Innovations Limited | Treatment of idiopathic pulmonary fibrosis |
| GB202016604D0 (en) | 2020-10-20 | 2020-12-02 | Univ Of Oxford | Compositions and methods for inducing an immune response |
| GB202017673D0 (en) | 2020-11-09 | 2020-12-23 | Imperial College Innovations Ltd | Treatment of pulmonary arterial hypertensive |
| TW202237164A (zh) * | 2020-12-04 | 2022-10-01 | 美商磨石生物公司 | 組合物及其使用方法 |
| GB202019454D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
| GB202019455D0 (en) | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for producing virus |
| JP2024509756A (ja) | 2021-02-19 | 2024-03-05 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | 安定化された融合前rsv fb抗原 |
| WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
| US20220265813A1 (en) | 2021-02-23 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Trimer Stabilizing HIV Envelope Protein Mutation |
| AU2022249741A1 (en) | 2021-04-01 | 2023-09-21 | Msd International Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| GB202105277D0 (en) | 2021-04-13 | 2021-05-26 | Imperial College Innovations Ltd | Signal peptides |
| WO2022234283A1 (en) | 2021-05-07 | 2022-11-10 | Astrazeneca Uk Limited | Compositions and methods for inducing an immune response |
| WO2023020939A1 (en) | 2021-08-17 | 2023-02-23 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023026182A1 (en) | 2021-08-24 | 2023-03-02 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| WO2023047348A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized corona virus spike protein fusion proteins |
| WO2023047349A1 (en) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceuticals, Inc. | Stabilized coronavirus spike protein fusion proteins |
| WO2023105221A1 (en) | 2021-12-07 | 2023-06-15 | Vaccitech (Uk) Limited | Vaccine boost methods and compositions |
| WO2023111725A1 (en) | 2021-12-14 | 2023-06-22 | Janssen Pharmaceuticals, Inc. | Sars-cov-2 vaccines |
| EP4448802A1 (en) | 2021-12-16 | 2024-10-23 | Janssen Vaccines & Prevention B.V. | Stabilized pre-fusion hmpv fusion proteins |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2024061757A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Pre-fusion human piv1 f proteins |
| WO2024061759A1 (en) | 2022-09-23 | 2024-03-28 | Janssen Vaccines & Prevention B.V. | Stabilized coronavirus s proteins |
| IL319934A (en) | 2022-10-06 | 2025-05-01 | Msd Int Business Gmbh | Stabilized pre-fusion piv3 f proteins |
| WO2024084441A1 (en) | 2022-10-19 | 2024-04-25 | Aelix Therapeutics, S.L. | Combination hiv vaccine |
| EP4608437A2 (en) | 2022-10-25 | 2025-09-03 | Barinthus Biotherapeutics North America, Inc. | Combination treatment regimes for treating cancer |
| GB202301244D0 (en) | 2023-01-27 | 2023-03-15 | Univ Oxford Innovation Ltd | Vaccine |
| GB202303328D0 (en) | 2023-03-07 | 2023-04-19 | Imperial College Innovations Ltd | Synthetic promoters |
| GB202305535D0 (en) | 2023-04-14 | 2023-05-31 | Imperial College Innovations Ltd | Oligonucleotide decoy |
| WO2024218165A1 (en) | 2023-04-17 | 2024-10-24 | Barinthus Biotherapeutics (Uk) Limited | Hpv viral vector vaccine |
| WO2025017540A1 (en) | 2023-07-20 | 2025-01-23 | Aelix Therapeutics, S.L. | Method of treatment of hiv infection with vaccine |
| CN117089577B (zh) * | 2023-08-21 | 2024-06-25 | 暨南大学 | 重组的猴腺病毒、病毒载体及构建方法 |
| WO2025052130A1 (en) | 2023-09-05 | 2025-03-13 | Oxford University Innovation Limited | Monoclonal antibody directed to reticulocyte-binding protein homologue 5 (pfrh5) |
| GB202400424D0 (en) | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025168946A1 (en) | 2024-02-09 | 2025-08-14 | Oxford University Innovation Limited | Pfrh5 immunogen |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3650939A (en) | 1964-11-12 | 1972-03-21 | Ppg Industries Inc | Alkali chlorine cell |
| CA2271450A1 (en) | 1999-05-12 | 2000-11-12 | Stuart Energy Systems Inc. | Hydrogen fuel replenishment process and apparatus |
| US20040136963A1 (en) * | 2001-06-22 | 2004-07-15 | The Trustees Of The University Of Pennsylvania | Simian adenovirus vectors and methods of use |
| SG2013034475A (en) * | 2001-11-21 | 2016-10-28 | Univ Pennsylvania | Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use |
| US20070205342A1 (en) | 2002-01-23 | 2007-09-06 | Edward Gabriel | Slip drive for leveling devices |
| US7481858B2 (en) | 2005-02-25 | 2009-01-27 | Societe Bic | Hydrogen generating fuel cell cartridges |
| EP2163260B1 (en) * | 2004-01-23 | 2017-03-15 | MSD Italia S.r.l. | Chimpanzee adenovirus vaccine carriers |
| US7617018B2 (en) | 2004-10-18 | 2009-11-10 | Innovative Design Solutions | Platform attitude adjustment augmentation method and apparatus |
| US7178337B2 (en) | 2004-12-23 | 2007-02-20 | Tassilo Pflanz | Power plant system for utilizing the heat energy of geothermal reservoirs |
| CN100578676C (zh) * | 2005-01-12 | 2010-01-06 | 明基电通股份有限公司 | 可调式升降支撑装置 |
| US20100143302A1 (en) * | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20090110695A1 (en) * | 2006-03-27 | 2009-04-30 | Menzo Jans Emko Havenga | Compositions Comprising a Recombinant Adenovirus and an Adjuvant |
| EP2333091B1 (en) * | 2007-05-29 | 2017-06-21 | Nature Technology Corporation | Vectors and methods for genetic immunization |
| SI2220241T1 (sl) * | 2007-11-28 | 2017-02-28 | The Trustees Of The University Of Pennsylvania | Adenovirus, ki obsega kapsidni heksonski protein opičjega E adenovirusa SAdV-39, in njegove uporabe |
| CA2754743C (en) * | 2009-03-10 | 2020-08-25 | Baylor Research Institute | Antigen presenting cell targeted anti-viral vaccines |
| GB201108879D0 (en) * | 2011-05-25 | 2011-07-06 | Isis Innovation | Vector |
-
2011
- 2011-05-25 GB GBGB1108879.6A patent/GB201108879D0/en not_active Ceased
-
2012
- 2012-05-25 ES ES12723726.1T patent/ES2659183T3/es active Active
- 2012-05-25 US US14/119,413 patent/US9714435B2/en active Active
- 2012-05-25 NO NO12723726A patent/NO2714916T3/no unknown
- 2012-05-25 SG SG2013087747A patent/SG195181A1/en unknown
- 2012-05-25 BR BR112013030222A patent/BR112013030222A2/pt not_active IP Right Cessation
- 2012-05-25 DK DK12723726.1T patent/DK2714916T3/en active
- 2012-05-25 EP EP17204780.5A patent/EP3321367B1/en active Active
- 2012-05-25 RU RU2013152648/10A patent/RU2013152648A/ru not_active Application Discontinuation
- 2012-05-25 JP JP2014511948A patent/JP6230527B2/ja active Active
- 2012-05-25 CA CA2837274A patent/CA2837274C/en active Active
- 2012-05-25 SG SG10201604179VA patent/SG10201604179VA/en unknown
- 2012-05-25 AU AU2012270144A patent/AU2012270144B2/en active Active
- 2012-05-25 CN CN201280036659.1A patent/CN103930551B/zh active Active
- 2012-05-25 WO PCT/GB2012/000467 patent/WO2012172277A1/en not_active Ceased
- 2012-05-25 EP EP12723726.1A patent/EP2714916B1/en active Active
-
2013
- 2013-12-02 ZA ZA2013/09016A patent/ZA201309016B/en unknown
-
2017
- 2017-06-20 US US15/628,277 patent/US10646587B2/en active Active
-
2020
- 2020-04-15 US US16/849,301 patent/US11857640B2/en active Active
-
2021
- 2021-06-28 FR FR21C1026C patent/FR21C1026I1/fr active Active
- 2021-07-07 NO NO2021028C patent/NO2021028I1/no unknown
-
2023
- 2023-11-16 US US18/511,357 patent/US20240181078A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014516536A5 (OSRAM) | ||
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| CN1067722C (zh) | 腺病毒载体 | |
| JP6970647B2 (ja) | シミアン(ゴリラ)アデノウイルス又はアデノウイルスベクター、及び使用方法 | |
| JP6970059B2 (ja) | アーフェンアデノウイルス(ゴリラ)又はアデノウイルスベクター、及び使用方法 | |
| JP2015057052A5 (OSRAM) | ||
| JP2017514483A5 (OSRAM) | ||
| JP2020511940A5 (OSRAM) | ||
| CN102586327B (zh) | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 | |
| CN104212802B (zh) | 一种肿瘤细胞广谱高活性启动子及其用途 | |
| CA2779632A1 (en) | Simian adenovirus and methods of use | |
| CN104846013A (zh) | 一种复制缺陷型人55型腺病毒载体及其制备方法和应用 | |
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| JP2005536231A (ja) | アデノウイルスに細胞選択的複製をもたらすための、スプライセオソーム媒介型rnaトランススプライシングの使用 | |
| JP2020537526A (ja) | Rsv抗原性タンパク質又はその断片をコードする2つの発現カセットを有するアデノウイルスベクター | |
| JP2021500880A (ja) | 2つの発現カセットを有するサルアデノウイルスベクター | |
| JP2000157289A5 (OSRAM) | ||
| Wen et al. | Construction and immune evaluation of the recombinant duck adenovirus type 3 delivering capsid protein VP1 of the type 1 duck hepatitis virus | |
| CN103555765A (zh) | 一种转录调控肿瘤靶向复制溶瘤腺病毒载体、携带治疗基因腺病毒及其制备方法和应用 | |
| JP2024501841A (ja) | アデノウイルス血清型35ヘルパーベクター | |
| JP2022552870A (ja) | 改変型アデノウイルスヘキソンタンパク質を有するアデノウイルス | |
| CN117417962B (zh) | 一种多靶点溶瘤腺病毒的构建方法及应用 | |
| JP6153205B2 (ja) | Va遺伝子破壊アデノウイルスベクターおよびそれを調製するための前駆体ベクター | |
| JP7711050B2 (ja) | アデノウイルスベクターおよびその使用 | |
| CN1231598C (zh) | 一种重组禽腺病毒的制备方法 |